Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma

Abstract

Background: The efficacy of immune checkpoint blockade therapy in patients with hepatocellular carcinoma (HCC) remains poor. Although serine- and arginine-rich splicing factor (SRSF) family members play crucial roles in tumors, their impact on tumor immunology remains unclear. This study aimed to elucidate the role of SRSF10 in HCC immunotherapy.

Methods: To identify the key genes associated with immunotherapy resistance, we conducted single-nuclear RNA sequencing, multiplex immunofluorescence, and The Cancer Genome Atlas and Gene Expression Omnibus database analyses. We investigated the biological functions of SRSF10 in immune evasion using in vitro co-culture systems, flow cytometry, various tumor-bearing mouse models, and patient-derived organotypic tumor spheroids.

Results: SRSF10 was upregulated in various tumors and associated with poor prognosis. Moreover, SRSF10 positively regulated lactate production, and SRSF10/glycolysis/ histone H3 lysine 18 lactylation (H3K18la) formed a positive feedback loop in tumor cells. Increased lactate levels promoted M2 macrophage polarization, thereby inhibiting CD8⁺ T cell activity. Mechanistically, SRSF10 interacted with the 3’-untranslated region of MYB, enhancing MYB RNA stability, and subsequently upregulating key glycolysis-related enzymes including glucose transporter 1 (GLUT1), hexokinase 1 (HK1), lactate dehydrogenase A (LDHA), resulting in elevated intracellular and extracellular lactate levels. Lactate accumulation induced histone lactylation, which further upregulated SRSF10 expression. Additionally, lactate produced by tumors induced lactylation of the histone H3K18la site upon transport into macrophages, thereby activating transcription and enhancing pro-tumor macrophage activity. M2 macrophages, in turn, inhibited the enrichment of CD8⁺ T cells and the proportion of interferon-γ⁺CD8⁺ T cells in the tumor microenvironment (TME), thus creating an immunosuppressive TME. Clinically, SRSF10 could serve as a biomarker for assessing immunotherapy resistance in various solid tumors. Pharmacological targeting of SRSF10 with a selective inhibitor 1C8 enhanced the efficacy of programmed cell death 1 (PD-1) monoclonal antibodies (mAbs) in both murine and human preclinical models.

Conclusions: The SRSF10/MYB/glycolysis/lactate axis is critical for triggering immune evasion and anti-PD-1 resistance. Inhibiting SRSF10 by 1C8 may overcome anti-PD-1 tolerance in HCC.

Keywords

Glycolysis / Histone lactylation / Immune checkpoint blockade / Serine and arginine rich splicing factor 10 / Tumor-Associated Macrophage

References

[1] SungH, FerlayJ, SiegelRL, Laversanne M, SoerjomataramI, JemalA, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-49.

[2] FornerA, ReigM, BruixJ. Hepatocellular carcinoma. Lancet (London, England). 2018; 391(10127): 1301-14.

[3] AllemaniC, Matsuda T, Di CarloV, HarewoodR, MatzM, NikšićM, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018; 391(10125): 1023-75.

[4] PinterM, Scheiner B, PinatoDJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023; 8(8): 760-70.

[5] EggermontAMM, BlankCU, MandalaM, Long GV, AtkinsonV, DalleS, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19): 1789-801.

[6] FinnRS, QinS, IkedaM, Galle PR, DucreuxM, KimTY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20): 1894-905.

[7] YauT, ParkJW, FinnRS, Cheng AL, MathurinP, EdelineJ, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022; 23(1): 77-90.

[8] QinS, ChanSL, GuS, BaiY, RenZ, LinX, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023; 402(10408): 1133-46.

[9] TianZ, HouX, LiuW, HanZ, WeiL. Macrophages and hepatocellular carcinoma. Cell & Bioscience. 2019; 9: 79.

[10] YunnaC, MengruH, LeiW, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020; 877: 173090.

[11] TariqueAA, LoganJ, ThomasE, Holt PG, SlyPD, FantinoE. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015; 53(5): 676-88.

[12] Shapouri-MoghaddamA, Mohammadian S, VaziniH, TaghadosiM, Esmaeili S-A, MardaniF, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018; 233(9): 6425-40.

[13] XiaoH, GuoY, LiB, LiX, WangY, Han S, et al. M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects. ACS Central Science. 2020; 6(7): 1208-22.

[14] HanahanD. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31-46.

[15] ChangCH, QiuJ, O’SullivanD, BuckMD, Noguchi T, CurtisJD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6): 1229-41.

[16] BuckMD, SowellRT, KaechSM, Pearce EL. Metabolic Instruction of Immunity. Cell. 2017; 169(4): 570-86.

[17] QianY, Galan-Cobo A. GuijarroI, DangM, Molkentine D, PoteeteA, et al. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023; 41(7): 1363-80 e7.

[18] GuoD, TongY, JiangX, Meng Y, JiangH, DuL, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IkappaBalpha. Cell Metab. 2022; 34(9): 1312-24 e6.

[19] CasconeT, McKenzie JA, MbofungRM, PuntS, WangZ, XuC, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018; 27(5): 977-87 e4.

[20] DuJX, ZhuGQ, CaiJL, Wang B, LuoYH, ChenC, et al. Splicing factors: Insights into their regulatory network in alternative splicing in cancer. Cancer Lett. 2021; 501: 83-104.

[21] ZhangC, ChenY, LiF, YangM, MengF, Zhang Y, et al. B7-H3 is spliced by SRSF3 in colorectal cancer. Cancer Immunol Immunother. 2021; 70(2): 311-21.

[22] PeiqiL, Zhaozhong G, YaotianY, JunJ, JihuaG, RongJ. Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma. Int J Med Sci. 2016; 13(7): 533-9.

[23] GaoX, DaiC, HuangS, Tang J, ChenG, LiJ, et al. Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clin Cancer Res. 2019; 25(4): 1291-301.

[24] KimHR, LeeGO, ChoiKH, Kim DK, RyuJS, HwangKE, et al. SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer. Lung Cancer. 2016; 99: 57-65.

[25] ChenS, YangC, WangZW, Hu JF, PanJJ, LiaoCY, et al. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. J Hematol Oncol. 2021; 14(1): 60.

[26] ChenY, HuangQ, LiuW, ZhuQ, CuiCP, Xu L, et al. Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth. Nat Commun. 2018; 9(1): 2464.

[27] LiuF, DaiM, XuQ, ZhuX, ZhouY, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis. Oncogene. 2018; 37(18): 2394-409.

[28] ZhouX, LiX, ChengY, Wu W, XieZ, XiQ, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014; 5: 4581.

[29] ChangC, Rajasekaran M, QiaoY, DongH, WangY, XiaH, et al. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nat Commun. 2022; 13(1): 1363.

[30] ChabrollesH, Auclair H, VegnaS, LahlaliT, PonsC, MicheletM, et al. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. PLoS Pathog. 2020; 16(11): e1008593.

[31] SeymourL, Bogaerts J, PerroneA, FordR, Schwartz LH, MandrekarS, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3): e143-e52.

[32] EisenhauerEA, Therasse P, BogaertsJ, SchwartzLH, Sargent D, FordR, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-47.

[33] AmezquitaRA, LunATL, BechtE, Carey VJ, CarppLN, GeistlingerL, et al. Orchestrating single-cell analysis with Bioconductor. Nat Methods. 2020; 17(2): 137-45.

[34] LuY, YangA, QuanC, Pan Y, ZhangH, LiY, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022; 13(1): 4594.

[35] MaL, Hernandez MO, ZhaoY, MehtaM, TranB, KellyM, et al. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell. 2019; 36(4).

[36] BiK, HeMX, BakounyZ, Kanodia A, NapolitanoS, WuJ, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021; 39(5).

[37] JenkinsRW, ArefAR, LizottePH, Ivanova E, StinsonS, ZhouCW, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018; 8(2): 196-215.

[38] Pais FerreiraD, SilvaJG, WyssT, Fuertes MarracoSA, Scarpellino L, CharmoyM, et al. Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. Immunity. 2020; 53(5).

[39] FaubertB, LiKY, CaiL, Hensley CT, KimJ, ZachariasLG, et al. Lactate Metabolism in Human Lung Tumors. Cell. 2017; 171(2).

[40] HuiS, Ghergurovich JM, MorscherRJ, JangC, TengX, LuW, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017; 551(7678): 115-8.

[41] AhmedK, TunaruS, TangC, Müller M, GilleA, SassmannA, et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 2010; 11(4): 311-9.

[42] VardjanN, Chowdhury HH, HorvatA, VelebitJ, MalnarM, MuhičM, et al. Enhancement of Astroglial Aerobic Glycolysis by Extracellular Lactate-Mediated Increase in cAMP. Front Mol Neurosci. 2018; 11: 148.

[43] LathamT, MackayL, SproulD, Karim M, CulleyJ, HarrisonDJ, et al. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res. 2012; 40(11): 4794-803.

[44] ZhangD, TangZ, HuangH, Zhou G, CuiC, WengY, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019; 574(7779): 575-80.

[45] FangY, LiuW, TangZ, Ji X, ZhouY, SongS, et al. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology (Baltimore, Md). 2023; 77(1): 109-23.

[46] PandkarMR, SinhaS, SamaiyaA, Shukla S. Oncometabolite lactate enhances breast cancer progression by orchestrating histone lactylation-dependent c-Myc expression. Transl Oncol. 2023; 37: 101758.

[47] ShkretaL, Blanchette M, ToutantJ, WilhelmE, BellB, StoryBA, et al. Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication. Nucleic Acids Res. 2017; 45(7): 4051-67.

[48] ChangC, Rajasekaran M, QiaoY, DongH, WangY, XiaH, et al. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nat Commun. 2022; 13(1): 1363.

[49] van de WeteringM, Francies HE, FrancisJM, BounovaG, IorioF, PronkA, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4): 933-45.

[50] BroutierL, Mastrogiovanni G, VerstegenMM, FranciesHE, Gavarro LM, BradshawCR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017; 23(12): 1424-35.

[51] ArefAR, Campisi M, IvanovaE, PortellA, LariosD, PielBP, et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 2018; 18(20): 3129-43.

[52] KalbasiA, RibasA. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020; 20(1): 25-39.

[53] LiM, YangY, XiongL, Jiang P, WangJ, LiC. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023; 16(1): 80.

[54] BrandA, SingerK, KoehlGE, Kolitzus M, SchoenhammerG, ThielA, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016; 24(5): 657-71.

[55] MaJ, TangL, TanY, XiaoJ, WeiK, ZhangX, et al. Lithium carbonate revitalizes tumor-reactive CD8+ T cells by shunting lactic acid into mitochondria. Nat Immunol. 2024; 25(3): 552-61.

[56] FengQ, LiuZ, YuX, HuangT, ChenJ, Wang J, et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022; 13(1): 4981.

[57] ZhangL, LiS. Lactic acid promotes macrophage polarization through MCT-HIF1α signaling in gastric cancer. Exp Cell Res. 2020; 388(2): 111846.

[58] GouY, WangH, WangT, Wang H, WangB, JiaoN, et al. Ectopic endometriotic stromal cells-derived lactate induces M2 macrophage polarization via Mettl3/Trib1/ERK/STAT3 signalling pathway in endometriosis. Immunology. 2023; 168(3): 389-402.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.